House eyes FDA technology and resources

Executive Summary

Even before the fiscal year 2009 budget is proposed, the House Energy and Commerce Oversight Subcommittee is beginning to assess FDA resources. A November report from an FDA Science Board subcommittee decries weaknesses in the agency's regulatory science and inadequate scientific expertise. FDA Commissioner Andrew von Eschenbach, General Accounting Office officials and Science Board members are among those scheduled to testify at the Jan. 29 hearing to address the report, which claims resources are key to reversing FDA's scientific decline (1"The Pink Sheet" Dec. 10, 2007, p. 15)...